Top

Angiogenesis

Published in:

01-12-2008 | Original Paper

PPARγ ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis

Authors: Ahmad Aljada, Laura O’Connor, Yu-Yen Fu, Shaker A. Mousa

Published in: Angiogenesis | Issue 4/2008

Abstract

Objective

To study the effect of peroxisome proliferator-activated receptor-gamma (PPARγ) agonists, pioglitazone and rosiglitazone, on vascular endothelial growth factor (VEGF)- and basic fibroblast growth factor (bFGF)-induced angiogenesis and on endothelial cell migration.

Methods

Chick chorioallantoic membrane (CAM) model was used to evaluate the efficacy of pioglitazone and rosiglitazone on VEGF- and bFGF-induced angiogenesis. In addition, the effect of pioglitazone and rosiglitazone on endothelial cell migration was evaluated using 8 mm pore filter to a feeder layer containing vitronectin as chemoattractant.

Results

Pioglitazone and rosiglitazone inhibited the pro-angiogenic effects of bFGF and VEGF in the CAM model significantly (P < 0.001) to the same extent. Endothelial cell migration was also inhibited by both pioglitazone and rosiglitazone (P < 0.001).

Conclusions

These results suggest that PPARγ ligands, pioglitazone and rosiglitazone, in addition to their important regulatory role in adipogenesis and inflammation, possess anti-angiogenic properties. Thus, PPARγ ligands may be useful in the treatment of diabetic retinopathy, macular degeneration, and other ocular disorders and may lower the risk to develop cancer in diabetic patients.

Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT (2004) Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 13:1646–1650PubMed

Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167. doi:10.1093/aje/kwh161 PubMedCrossRef

Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N (2004) Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 13:915–919PubMed

Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S (2006) Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871–1877. doi:10.1001/archinte.166.17.1871 PubMedCrossRef

Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP et al (2008) Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 47:1856–1862. doi:10.1002/hep.22251 PubMedCrossRef

Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM et al (1998) Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 4:1058–1061. doi:10.1038/2042 PubMedCrossRef

Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M et al (1998) Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1:465–470. doi:10.1016/S1097-2765(00)80047-7 PubMedCrossRef

Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM (1998) PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241–252. doi:10.1016/S0092-8674(00)81575-5 PubMedCrossRef

Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93:229–240. doi:10.1016/S0092-8674(00)81574-3 PubMedCrossRef

10.

Escher P, Wahli W (2000) Peroxisome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res 448:121–138. doi:10.1016/S0027-5107(99)00231-6 PubMed

11.

Yajima K, Hirose H, Fujita H, Seto Y, Fujita H, Ukeda K et al (2003) Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab 284:E966–E971PubMed

12.

Keshamouni VG, Arenberg DA, Reddy RC, Newstead MJ, Anthwal S, Standiford TJ (2005) PPAR-gamma activation inhibits angiogenesis by blocking ELR + CXC chemokine production in non-small cell lung cancer. Neoplasia 7:294–301. doi:10.1593/neo.04601 PubMedCrossRef

13.

Kolak M, Yki-Jarvinen H, Kannisto K, Tiikkainen M, Hamsten A, Eriksson P et al (2007) Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab 92:720–724. doi:10.1210/jc.2006-1465 PubMedCrossRef

14.

Jha RJ (1999) Thiazolidinediones–the new insulin enhancers. Clin Exp Hypertens 21:157–166PubMedCrossRef

15.

Lebovitz HE, Banerji MA (2001) Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 56:265–294. doi:10.1210/rp.56.1.265 PubMedCrossRef

16.

(2000) Actos (pioglitazone HCL) provides a safe, effective alternative for patients formerly taking Rezulin. Diabetes Technol Ther 2:290–291

17.

Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932–936. doi:10.1038/nature04478 PubMedCrossRef

18.

Risau W (1997) Mechanisms of angiogenesis. Nature 386:671–674. doi:10.1038/386671a0 PubMedCrossRef

19.

Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62. doi:10.1126/science.1104819 PubMedCrossRef

20.

De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello MR, Aldinucci D et al (2008) The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214:559–567. doi:10.1002/jcp.21260 PubMedCrossRef

21.

Mousa SA, O’Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ (2005) The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. J Cardiovasc Pharmacol 46:356–360. doi:10.1097/01.fjc.0000175438.94906.a0 PubMedCrossRef

22.

Colman RW, Pixley RA, Sainz IM, Song JS, Isordia-Salas I, Muhamed SN et al (2003) Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J Thromb Haemost 1:164–170. doi:10.1046/j.1538-7836.2003.00025.x PubMedCrossRef

23.

Bozarth J, Penno M (1997) SAM: an improved method for the quantitation of cellular migration–role of avb3 integrin in endothelial and smooth muscle cell migration. Methods Cell Sci 19:179–187. doi:10.1023/A:1009789416463 CrossRef

24.

Lemberger T, Desvergne B, Wahli W (1996) Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 12:335–363. doi:10.1146/annurev.cellbio.12.1.335 PubMedCrossRef

25.

Fruchart JC, Duriez P, Staels B (1999) Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 10:245–257. doi:10.1097/00041433-199906000-00007 PubMedCrossRef

26.

Suchanek KM, May FJ, Robinson JA, Lee WJ, Holman NA, Monteith GR et al (2002) Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol Carcinog 34:165–171. doi:10.1002/mc.10061 PubMedCrossRef

27.

Engel J, Rabba J, Schild D (1996) A transient, RCK4-like K+ current in cultured Xenopus olfactory bulb neurons. Pflugers Arch 432:845–852. doi:10.1007/s004240050207 PubMedCrossRef

28.

Xin X, Yang S, Kowalski J, Gerritsen ME (1999) Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274:9116–9121. doi:10.1074/jbc.274.13.9116 PubMedCrossRef

29.

Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J (1999) PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19:546–551PubMed

30.

Satoh H, Tsukamoto K, Hashimoto Y, Hashimoto N, Togo M, Hara M et al (1999) Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. Biochem Biophys Res Commun 254:757–763. doi:10.1006/bbrc.1998.0126 PubMedCrossRef

31.

Panigrahy D, Huang S, Kieran MW, Kaipainen A (2005) PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 4:687–693PubMedCrossRef

32.

Murata T, He S, Hangai M, Ishibashi T, Xi XP, Kim S et al (2000) Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization. Invest Ophthalmol Vis Sci 41:2309–2317PubMed

33.

Goetze S, Eilers F, Bungenstock A, Kintscher U, Stawowy P, Blaschke F et al (2002) PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 293:1431–1437. doi:10.1016/S0006-291X(02)00385-6 PubMedCrossRef

34.

Goetze S, Bungenstock A, Czupalla C, Eilers F, Stawowy P, Kintscher U et al (2002) Leptin induces endothelial cell migration through Akt, which is inhibited by PPARgamma-ligands. Hypertension 40:748–754. doi:10.1161/01.HYP.0000035522.63647.D3 PubMedCrossRef

35.

Huang H, Campbell SC, Bedford DF, Nelius T, Veliceasa D, Shroff EH et al (2004) Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510. Mol Cancer Res 2:541–550PubMed

36.

Panigrahy D, Singer S, Shen LQ, Butterfield CE, Freedman DA, Chen EJ et al (2002) PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110:923–932PubMed

37.

Sierra-Honigmann MR, Nath AK, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa WC et al (1998) Biological action of leptin as an angiogenic factor. Science 281:1683–1686. doi:10.1126/science.281.5383.1683 PubMedCrossRef

38.

Giannini S, Serio M, Galli A (2004) Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 27:982–991PubMed

39.

Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027. doi:10.1200/JCO.2005.06.081 PubMedCrossRef

40.

Fahmy RG, Dass CR, Sun LQ, Chesterman CN, Khachigian LM (2003) Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth. Nat Med 9:1026–1032. doi:10.1038/nm905 PubMedCrossRef

41.

Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844. doi:10.1038/362841a0 PubMedCrossRef

42.

Yan W, Bentley B, Shao R (2008) Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. Mol Biol Cell 19:2278–2288. doi:10.1091/mbc.E07-10-1068 PubMedCrossRef

43.

Michalik L, Desvergne B, Wahli W (2004) Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4:61–70. doi:10.1038/nrc1254 PubMedCrossRef

44.

Kaipainen A, Kieran MW, Huang S, Butterfield C, Bielenberg D, Mostoslavsky G (2007) PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS ONE 2:e260. doi:10.1371/journal.pone.0000260 PubMedCrossRef

45.

Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnes CM, Fannon M et al (2008) PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 105:985–990. doi:10.1073/pnas.0711281105 PubMedCrossRef

46.

Strickler HD, Wylie-Rosett J, Rohan T, Hoover DR, Smoller S, Burk RD et al (2001) The relation of type 2 diabetes and cancer. Diabetes Technol Ther 3:263–274. doi:10.1089/152091501300209633 PubMedCrossRef

47.

Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L et al (2007) Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25:1476–1481. doi:10.1200/JCO.2006.07.2777 PubMedCrossRef

48.

Shen LQ, Child A, Weber GM, Folkman J, Aiello LP (2008) Rosiglitazone and delayed onset of proliferative diabetic retinopathy. Arch Ophthalmol 126:793–799. doi:10.1001/archopht.126.6.793 PubMedCrossRef

Title: PPARγ ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis
Authors: Ahmad Aljada
Laura O’Connor
Yu-Yen Fu
Shaker A. Mousa
Publication date: 01-12-2008
Publisher: Springer Netherlands
Published in: Angiogenesis / Issue 4/2008
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI: https://doi.org/10.1007/s10456-008-9118-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2008

A role for planar cell polarity signaling in angiogenesis

Angiogenic response to extracorporeal shock wave treatment in murine skin isografts

The chick embryo chorioallantoic membrane as a model to study tumor metastasis

Circulating and imaging markers for angiogenesis

A nuclease-resistant RNA aptamer specifically inhibits angiopoietin-1-mediated Tie2 activation and function

Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials